期刊文献+

PCSK9 siRNA对THP-1源性巨噬细胞CD36、SR-A1及SR-B1表达的影响 被引量:6

Effects of PCSK9 siRNA on CD36,SR-A1 and SR-B1 expression in THP-1 derived macrophages
下载PDF
导出
摘要 目的:研究前蛋白转换酶枯草溶菌素9(PCSK9)siRNA对THP-1源性巨噬细胞CD36、SR-A1及SR-B1表达的影响。方法:以THP-1源性巨噬细胞为研究对象,应用Lipofectamine 2000转染不同浓度PCSK9 siRNA进THP-1源性巨噬细胞中,RT-PCR及Western blot筛选出最有效的siRNA,再转染入THP-1源性巨噬细胞,24 h后加入ox-LDL处理24 h,采用油红O染色检测细胞内脂质蓄积情况,RT-PCR分析细胞CD36、SR-A1及SR-B1表达。结果:浓度为80 nmol/L的PCSK9 siRNA基因沉默效应最佳;油红O染色结果表明ox-LDL组细胞内脂质蓄积情况最为明显,PCSK9 siRNA转染组次之;PCSK9 siRNA转染组CD36 mRNA表达水平相对于ox-LDL组降低(P<0.05),而ox-LDL组和PCSK9 siRNA转染组SR-A1及SR-B1 mRNA表达无明显差异。结论:PCSK9可能通过影响摄取脂质的细胞膜表面受体CD36表达,参与动脉粥样硬化的发生发展。 Objective:To investigate the effects of PCSK9 siRNA on CD36,SR-A1 and SR-B1 expressions in THP-1 derived macrophages.Methods:The siRNA for PCSK9 gene were transfected into THP-1 derived macrophages using positive ion liposome Lipofectamine 2000.Transfection efficiency was assessed by fluorescence microscope assay.The expression of PCSK9 in THP-1 derived macrophages at 24 h after transfection was detected by RT-PCR and Western blot.The most efficient siRNA was selected for transfection.At 24 h after transfection,macrophages were treated with ox-LDL for another 24 h.Then the intracellular lipid accumulation was observed by oil red O staining,and expressions of CD36 mRNA,SR-A1 mRNA and SR-B1 mRNA were detected by RT-PCR.Results:siRNA of 80 nmol/L showed the strongest inhibition for the gene expression of PCSK9,and ox-LDL-induced accumulation of cholesterol and upregulation of CD36 mRNA expression in THP-1 derived macrophages decreased by application of PCSK9 siRNA(P 〈 0.05).However,PCSK9 siRNA caused no effect on ox-LDL-induced upregulation of SR-A1 mRNA and SR-B1 mRNA expression in macrophages.Conclusion:PCSK9 may be involved in atherosclerosis development by inhibiting the expression of CD36.
出处 《南京医科大学学报(自然科学版)》 CAS CSCD 北大核心 2011年第5期673-678,共6页 Journal of Nanjing Medical University(Natural Sciences)
基金 湖南省应用基础研究计划重点项目(2008FJ2006) 湖南省科技厅计划项目(2009TP4057-2,2010TP4008-2) 湖南省教育厅重点科研项目(10A105) 湖南省高校科技创新团队支持计划资助
关键词 前蛋白转换酶枯草溶菌素9 巨噬细胞 CD36 SR—A1 SR—B1 PCSK9 macrophages expression CD36 SR-A 1 SR-B 1
  • 相关文献

参考文献4

二级参考文献60

  • 1程艳丽,谢闵,刘录山,王贵学.pcsk9基因突变与胆固醇血症[J].中国生物化学与分子生物学报,2007,23(3):172-176. 被引量:6
  • 2Elagoz A, Benjannel S, Mammarbassi A, et al. Biosynthesis and cellular trafficking of the convertase SKI-1/SIP: eetodomain shedding requires SKI-1activity. J Biol Chem, 2002, 277 (13): 11265- 11275
  • 3Seidah N G, Benjannet S, Wickham L, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation.Proc Natl Acad Sci USA, 2003, 100(3): 928-933
  • 4Maxwell K N, Fisher E A, Breslow J L, et al. Over expression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc Natl Acad Sci USA, 2005, 102(6): 2069-2074
  • 5Poirier S, Prat A, Marcinkiewicz E, et al. Implication of the proprotein convertase PCSK9/NARC-1 in the development of the nervous system. J Neurochem, 2006, 98(3): 838-850
  • 6Peterson A S, Fong L G, Young S G. PCSK9 function and physiology. J Lipid Res, 2008, 49(6): 1152- 1156
  • 7Bingham B, Shen R, Kotnis S, et al. Proapoptotic effects ofNARC 1 (= PCSKg), the gene encoding a novel serine proteinase. Cytometry A, 2006, 69(11): 1123-1131
  • 8Brown M S, Goldstein J L. Lowing LDL-not only how low, but how long?. Science, 2006, 311(5768): 1721 - 1723
  • 9Libby P, Geng Y J, Aikawa M, et al. Macrophage and atherosclerotic plaque stability. Curr Opin Lipidol, 1996, 7(5): 330-335
  • 10Boyle J J. Macrophage activation in atherosclerosis: pathogenesis and pharmacology of plaque rupture, Curr Vasc Pharmacol, 2005, 3 (1): 63-68

共引文献36

同被引文献76

  • 1危当恒,王贵学,王佐,刘录山,吕运成,唐朝克.基质细胞衍生因子1对低密度脂蛋白诱导单核—内皮细胞粘附的影响[J].中国动脉硬化杂志,2006,14(5):387-390. 被引量:10
  • 2Abifadel M, Guerin M, Benjannet S, et al. Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia[J]. Atheroselerosis, 2012, 223(2) :394- 400.
  • 3Seidah NG, Benjannet S, Wickham L, et al. The secretory proprotein convertase neural apoptosis-regulated eonvertase 1 (NARC-1) :liver regeneration and neuronal differentiationl-J]. Proc Natl Acad Sci U S A, 2003, 100(3):928-933.
  • 4Hassan M, Latif N, Yacoub M. Adipose tissue: friend or foe [J]. Nat Rev Cardiol, 2012, 9(12):689-702.
  • 5Leren TP. Sorting an LDL receptor with bound PCSK9 to intracellular degradationEJ]. Atherosclerosis, 2014, 237 (1) 76-81.
  • 6Roth EM, McKenney JM, Hanotin C, et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia[J]. N Engl J Med, 2012, 367 (20) 1891-1900.
  • 7Lee P, Hegele RA. Current phase ]l proprotein eonvertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia [J]. Expert Opin Investig Drugs, 2013, 22(11) : 1411-1423.
  • 8Corral P. Back to basics: PCSK9 as a new target for the LDL receptor[J]. Arq Bras Cardiol, 2014, 102(1):e5-8.
  • 9Saavedra YG, Zhang J, Seidah NG. PCSK9 prosegmentchimera as novel inhibitors of LDLR degradation[J]. PLoS One, 2013, 8(8) :e72113.
  • 10Benjannet S, Hamelin J, Chr6tien M, et al. Loss-and gain-of- function PCSK9 variants: cleavage specificity, dominant negative effects, and low density lipoprotein receptor (LDLR) degradation[J]. J Biol Chem, 2012, 287(40) :33745-33755.

引证文献6

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部